Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2.
Ontology highlight
ABSTRACT: Repurposing studies have identified several FDA-approved compounds as potential inhibitors of the intracellular domain of epidermal growth factor receptor 1 (EGFR) and human epidermal receptor 2 (HER2). EGFR and HER2 represent important targets for the design of new drugs against different types of cancer, and recently, differences in affinity depending on active or inactive states of EGFR or HER2 have been identified. In this study, we first identified FDA-approved compounds with similar structures in the DrugBank to lapatinib and gefitinib, two known inhibitors of EGFR and HER2. The selected compounds were submitted to docking and molecular dynamics MD simulations with the molecular mechanics generalized Born surface area approach to discover the conformational and thermodynamic basis fo
SUBMITTER: Balbuena-Rebolledo I
PROVIDER: S-EPMC8401258 | biostudies-literature | 2021 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA